Document Detail


A topical treatment program for psoriasis with low anthralin concentrations.
MedLine Citation:
PMID:  342554     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A treatment program for psoriasis in which 0.01--0.05% anthralin was used has been clinically evaluated. In such low concentrations it is possible to use anthralin if one simultaneously avoids exposing the skin to unnecessary external mechanical trauma, including the mechanical removal of the scales from the lesions. Applied in this fashion, anthralin then also becomes most suitable for use in ambulatory therapy. In these low concentrations it does not irritate either the involved or the non-involved psoriatic skin. No discoloration of the clothes, the skin, the hair or the nails was observed.
Authors:
I Brody; A Johansson
Related Documents :
1357854 - Cutaneous cryptococcosis resembling molluscum contagiosum in a homosexual man with aids...
111624 - Dermopathic changes in hypozincemia.
9854164 - Sweet's syndrome associated with granulocyte colony-stimulating factor.
24244074 - Classification of small lesions in dynamic breast mri: eliminating the need for precise...
20086564 - Red plaque on a high school wrestler.
16015664 - Intussusceptions arising from two different sites in a child with cystic fibrosis.
Publication Detail:
Type:  Clinical Trial; Journal Article    
Journal Detail:
Title:  Journal of cutaneous pathology     Volume:  4     ISSN:  0303-6987     ISO Abbreviation:  J. Cutan. Pathol.     Publication Date:  1977 Oct 
Date Detail:
Created Date:  1978-04-17     Completed Date:  1978-04-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0425124     Medline TA:  J Cutan Pathol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  233-43     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Topical
Adolescent
Adult
Aged
Anthracenes / therapeutic use*
Anthralin / administration & dosage,  adverse effects,  therapeutic use*
Child
Child, Preschool
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Evaluation
Female
Humans
Male
Middle Aged
Psoriasis / drug therapy*
Chemical
Reg. No./Substance:
0/Anthracenes; 480-22-8/Anthralin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  High-dose furosemide in Nigerians with severe chronic renal failure: effect on fecal water content.
Next Document:  Clear and dark basal keratinocytes in human epidermis. A stereologic study.